NR3C2 and myocardial infarction: A post hoc analysis of the EPHESUS trial demonstrated a greater total risk reduction in heart failure after myocardial infarction in diabetic patients than in nondiabetic individuals treated with eplerenone (EPL)—a selective mineralocorticoid receptor (MR) antagonist [21].